These innovative molecules represent a significant advancement in the therapy of type 2 diabetes. Retatrutide, a dual GLP-1 and GIP receptor agonist, demonstrates promising efficacy in lowering blood glucose levels. https://mollywwtu947562.ka-blogs.com/92331624/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide